open access
Yellow fever vaccine-associated neurotropic disease (YEL-AND) – A case report
Affiliations- Chair & Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland
open access
Abstract
Yellow fever (YF) is a mosquito-borne viral hemorrhagic fever, which is a serious and potentially fatal disease with no specific antiviral treatment that can be effectively prevented by an attenuated vaccine (YEL). Despite the long history of safe and efficacious YF vaccination, sporadic case reports of serious adverse events (SAEs) have been reported, including yellow fever vaccine-associated neurotropic disease (YEL-AND). YEL-AND usually appears within one month of YF vaccination, manifesting as meningoencephalitis, Guillain–Barré syndrome (GBS) or acute disseminated encephalomyelitis (ADEM). We report a case of YEL-AND with meningitis presentation in a 39-year-old Caucasian man without evidence of significant risk factors, which was confirmed by the presence of the YF virus and specific immunoglobulin G (IgG) antibodies in the cerebrospinal fluid (CSF). In conclusion, we should stress the importance of balancing the risk of SAEs associated with the vaccine and the benefits of YF vaccination for each patient individually.
Abstract
Yellow fever (YF) is a mosquito-borne viral hemorrhagic fever, which is a serious and potentially fatal disease with no specific antiviral treatment that can be effectively prevented by an attenuated vaccine (YEL). Despite the long history of safe and efficacious YF vaccination, sporadic case reports of serious adverse events (SAEs) have been reported, including yellow fever vaccine-associated neurotropic disease (YEL-AND). YEL-AND usually appears within one month of YF vaccination, manifesting as meningoencephalitis, Guillain–Barré syndrome (GBS) or acute disseminated encephalomyelitis (ADEM). We report a case of YEL-AND with meningitis presentation in a 39-year-old Caucasian man without evidence of significant risk factors, which was confirmed by the presence of the YF virus and specific immunoglobulin G (IgG) antibodies in the cerebrospinal fluid (CSF). In conclusion, we should stress the importance of balancing the risk of SAEs associated with the vaccine and the benefits of YF vaccination for each patient individually.
Keywords
Yellow fever vaccine, Adverse event, Neurological disease
About this articleTitle
Yellow fever vaccine-associated neurotropic disease (YEL-AND) – A case report
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
101-105
Page views
421
Article views/downloads
650
DOI
10.1016/j.pjnns.2016.09.002
Bibliographic record
Neurol Neurochir Pol 2017;51(1):101-105.
Keywords
Yellow fever vaccine
Adverse event
Neurological disease
Authors
Jolanta Florczak-Wyspiańska
Ewa Nawotczyńska
Wojciech Kozubski
